DTIL

NASDAQ 已收盘

Precision BioSciences, Inc.

7.28 USD
+0.07+3.12%
盘后 7.07 +0.14%
2026-08-03
市值
$187.84M
市盈率
EPS
-2.62
股息率
52 周区间
3.53 – 9.62
成交量
383.12K
Beta
1.23
目标价
29.60
52W 低 3.5352W 高 9.62
价格走势

公司简介

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ...